This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34. doi: 10.1200/JCO.2001.19.16.3622BalchCMSoongSJGershenwaldJEThompsonJFReintgenDSCascinelliNet alPrognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging systemJ Clin Oncol20011936223410.1200/JCO.2001.19.16.3622Open DOISearch in Google Scholar
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370: 599-609. doi: 10.1056/NEJMoa1310460MortonDLThompsonJFCochranAJMozzilloNNiewegOERosesDFet alFinal trial report of sentinel-node biopsy versus nodal observation in melanomaN Engl J Med201437059960910.1056/NEJMoa1310460Open DOISearch in Google Scholar
Moody JA, Botham SJ, Dahill KE, Wallace DL, Hardwicke JT. Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma - a systematic review of the literature. Eur J Surg Oncol 2017; 43:1760-7. doi: 10.1016/j.ejso.2017.07.003MoodyJABothamSJDahillKEWallaceDLHardwickeJTComplications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma - a systematic review of the literatureEur J Surg Oncol2017431760710.1016/j.ejso.2017.07.003Open DOISearch in Google Scholar
van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006; 17: 1578-85. doi: 10.1093/annonc/mdl176vanAkkooi ACdeWilt JHVerhoefCSchmitzPIvanGeel ANEggermontAMet alClinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?Ann Oncol20061715788510.1093/annonc/mdl176Open DOISearch in Google Scholar
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017; 376: 2211-22. doi: 10.1056/ NEJMoa1613210FariesMBThompsonJFCochranAJAndtbackaRHMozzilloNZagerJSet alCompletion dissection or observation for sentinel-node metastasis in melanomaN Engl J Med201737622112210.1056/NEJMoa1613210Open DOISearch in Google Scholar
Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al. Final analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol 2019; 37: 3000-8. doi: 10.1200/JCO.18.02306LeiterUStadlerRMauchCHohenbergerWBrockmeyerNHBerkingCet alFinal analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel nodeJ Clin Oncol2019373000810.1200/JCO.18.02306Open DOISearch in Google Scholar
Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer 2019; 119: 1-10. doi: 10.1016/j. ejca.2019.07.001EggermontAMMChiarion-SileniVGrobJJDummerRWolchokJDSchmidtHet alAdjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trialEur J Cancer201911911010.1016/j.ejca.2019.07.001Open DOISearch in Google Scholar
Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017; 377: 1813-23. doi: 10.1056/NEJMoa1708539LongGVHauschildASantinamiMAtkinsonVMandalaMChiarion-SileniVet alAdjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaN Engl J Med201737718132310.1056/NEJMoa1708539Open DOISearch in Google Scholar
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824-35. doi: 10.1056/NEJMoa1709030WeberJMandalaMDelVecchio MGogasHJAranceAMCoweyCLet alAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanomaN Engl J Med201737718243510.1056/NEJMoa1709030Open DOISearch in Google Scholar
Franke V, van Akkooi ACJ. The extent of surgery for stage III melanoma: how much is appropriate? Lancet Oncol 2019; 20: e167-e174. doi: 10.1016/ S1470-2045(19)30099-3FrankeVvanAkkooi ACJThe extent of surgery for stage III melanoma: how much is appropriate?Lancet Oncol201920e167e17410.1016/S1470-2045(19)30099-3Open DOISearch in Google Scholar
Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol 2020; 27: 15-21. doi: 10.1245/s10434-019-07830-wBelloDMFariesMBThe landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes)Ann Surg Oncol202027152110.1245/s10434-019-07830-wOpen DOISearch in Google Scholar
Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 2018; 25: 210510. doi: 10.1245/s10434-018-6513-7GershenwaldJEScolyerRAMelanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyondAnn Surg Oncol20182521051010.1245/s10434-018-6513-7Open DOISearch in Google Scholar
Blankenstein SA, van Akkooi ACJ. Adjuvant systemic therapy in high-risk melanoma. Melanoma Res 2019; 29: 358-64. doi: 10.1097/ CMR.0000000000000604BlankensteinSAvanAkkooi ACJAdjuvant systemic therapy in high-risk melanomaMelanoma Res2019293586410.1097/CMR.0000000000000604Open DOISearch in Google Scholar
Madu MF, Wouters MW, van Akkooi AC. Sentinel node biopsy in melanoma: Current controversies addressed. Eur J Surg Oncol 2017; 43: 517-33. doi: 10.1016/j.ejso.2016.08.007MaduMFWoutersMWvanAkkooi ACSentinel node biopsy in melanoma: Current controversies addressedEur J Surg Oncol2017435173310.1016/j.ejso.2016.08.007Open DOISearch in Google Scholar
Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9. doi: 10.1001/archsurg.1992.01420040034005MortonDLWenDRWongJHEconomouJSCagleLAStormFKet alTechnical details of intraoperative lymphatic mapping for early stage melanomaArch Surg1992127392910.1001/archsurg.1992.01420040034005Open DOISearch in Google Scholar
Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200: 314-9. doi: 10.1002/path.1365CookMGGreenMAAndersonBEggermontAMRuiterDJSpatzAet alThe development of optimal pathological assessment of sentinel lymph nodes for melanomaJ Pathol2003200314910.1002/path.1365Open DOISearch in Google Scholar
Delgado AF, Delgado AF. Complete lymph node dissection in melanoma: A systematic review and meta-analysis. Anticancer Res 2017; 37: 6825-9. doi: 10.21873/anticanres.12143DelgadoAFDelgadoAFComplete lymph node dissection in melanoma: A systematic review and meta-analysisAnticancer Res2017376825910.21873/anticanres.12143Open DOISearch in Google Scholar
Ma Q, Dieterich LC, Detmar M. Multiple roles of lymphatic vessels in tumor progression. Curr Opin Immunol 2018; 53: 7-12. doi: 10.1016/j. coi.2018.03.018MaQDieterichLCDetmarMMultiple roles of lymphatic vessels in tumor progressionCurr Opin Immunol20185371210.1016/j.coi.2018.03.018Open DOISearch in Google Scholar
Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol 2018; 36: 3441-9. doi: 10.1200/ JCO.18.01219HauschildADummerRSchadendorfDSantinamiMAtkinsonVMandalaMet alLonger follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanomaJ Clin Oncol2018363441910.1200/JCO.18.01219Open DOISearch in Google Scholar
Verver D, van KD, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, et al. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. Eur J Cancer 2018; 96: 25-33. doi: 10.1016/j.ejca.2018.02.022VerverDvanKDvan AkkooiACJRutkowskiPPowellBWEMRobertCet alRisk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerationsEur J Cancer201896253310.1016/j.ejca.2018.02.022Open DOISearch in Google Scholar
